Description

Drug Classification:

Rivaroxaban belongs to a class of medications known as direct oral anticoagulants (DOACs) or novel oral anticoagulants (NOACs). It works by inhibiting factor Xa, a key component in the blood clotting cascade, thereby preventing the formation of blood clots.

Formulations:

• Rivaroxaban Tablets:
  • Strength: Available in two strengths – 10mg and 20mg tablets.
  • Product Form: Oral tablets for convenient administration.
  • Packing Specifications: Packaged in blister packs containing 14 tablets each, ensuring ease of use and portability.

Indications:

Rivaroxaban Tablets are indicated for the following conditions:

• Prevention of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation: Rivaroxaban is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), a type of irregular heartbeat.
• Treatment and Prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Rivaroxaban is indicated for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), conditions characterized by the formation of blood clots in the veins.
• Prevention of Recurrent Venous Thromboembolism (VTE) in Adult Patients: Rivaroxaban is prescribed to prevent the recurrence of venous thromboembolism (VTE), including DVT and PE, in adult patients following initial treatment.

Usage:

• Rivaroxaban Tablets should be taken orally, with or without food, as directed by your healthcare provider.
• It is essential to adhere to the prescribed dosage and regimen recommended by your healthcare provider.
• Do not discontinue Rivaroxaban without consulting your doctor, as sudden discontinuation may increase the risk of thrombotic events.

Dosage:

• The recommended dosage of Rivaroxaban depends on the indication for which it is prescribed.
• For stroke prevention in NVAF, the typical dosage is 20 mg once daily with the evening meal.
• For the treatment and prevention of DVT and PE, the usual dosage is 15 mg twice daily for the first 21 days, followed by 20 mg once daily thereafter.
• Dosage adjustments may be necessary based on individual patient factors and renal function.

Pharmacokinetics:

• Rivaroxaban is rapidly absorbed after oral administration, with peak plasma concentrations reached within 2-4 hours.
• The drug undergoes hepatic metabolism primarily by the CYP3A4 enzyme system and is eliminated predominantly via the kidneys.
• The elimination half-life of Rivaroxaban is approximately 5-9 hours in healthy individuals.

Pharmacodynamics:

• Rivaroxaban inhibits factor Xa in the coagulation cascade, thereby preventing the conversion of prothrombin to thrombin and the subsequent formation of fibrin clots.
• By inhibiting factor Xa, Rivaroxaban effectively prevents the formation of new blood clots and reduces the risk of thrombotic events.

Side Effects:

• Common side effects of Rivaroxaban may include bleeding, bruising, dizziness, headache, and gastrointestinal disturbances.
• Serious side effects such as hemorrhage, allergic reactions, and liver injury are rare but may occur.
• Contact your healthcare provider immediately if you experience severe or persistent side effects while taking Rivaroxaban.

Experience the efficacy and convenience of Rivaroxaban Tablets from AIT Pharmaceuticals Division. Trust in our commitment to providing safe and effective medications to support your health and well-being. For more information, please visit our website or consult your healthcare provider.